Shots: The P-II Lauriet study evaluates the safety & efficacy of semorinemab (anti-tau mAb) vs PBO in 272 adult patients with AD across 43 centers globally. The therapy is being […]readmore
Tags : Semorinemab
Shots: The P-II TAURIEL study involves assessing of semorinemab vs PBO in 457 patients with early AD across 97 sites Genentech divulges that the P-II TAURIEL study did not meet […]readmore